Status:
UNKNOWN
Study of Risk Factors for Intraductal Papillary Mucinous Neoplasms Degeneration at the Nancy CHRU (IPMN)
Lead Sponsor:
Central Hospital, Nancy, France
Conditions:
Study of Risk Factors for IPMNs Degeneration at the Nancy CHRU
Eligibility:
All Genders
18+ years
Brief Summary
Cystic lesions of the pancreas are frequent with a risk of degeneration into adenocarcinoma with pejorative prognosis. IPMNs require characterization to clarify their potential for degeneration. Clin...
Detailed Description
This is a monoservice and monocentric retrospective study at the Nancy CHRU. We will study the risk factors for IPMNs degeneration in order to determine the most sensitive and specific. To do this, w...
Eligibility Criteria
Inclusion
- Patients with a Branch Duct, Main Duct or mixed IPMNs operated at the Nancy CHRU between September 2009 and October 2021, adults and without legal protection measures
Exclusion
- IPMNs not operated
- Pancreatic cancer without IPMNs
- Patients whose state of health contraindicates pancreatic surgery
- Non-adult patient
- Patients under legal protection
Key Trial Info
Start Date :
May 10 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 30 2021
Estimated Enrollment :
57 Patients enrolled
Trial Details
Trial ID
NCT04901364
Start Date
May 10 2021
End Date
October 30 2021
Last Update
May 25 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Jean-Baptiste CHEVAUX
Nancy, France, 54000